Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)

NCT00397722 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00397722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00397722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2006
Completion date
September 5, 2007
Enrollment
299 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

social phobia